Publikationen in Zusammenarbeit mit Forschern von Complexo Hospitalario Universitario de Santiago (22)

2024

  1. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2020

  1. Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

    Inflammatory bowel diseases, Vol. 26, Núm. 8, pp. 1149-1154

  2. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

  3. Effectiveness and safety of the switch from remicade® to CT-P13 in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 13, Núm. 11, pp. 1380-1386

  4. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

2018

  1. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279

2017

  1. Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab

    Revista Española de Enfermedades Digestivas, Vol. 109, Núm. 2, pp. 122-129

  2. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800

  3. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

  4. Incremento de peso en pacientes con fibrosis quística: ¿Es siempre beneficioso?

    Nutricion Hospitalaria, Vol. 34, Núm. 3, pp. 578-583

2016

  1. ESPGHAN 2012 guidelines for Coeliac disease diagnosis: Validation through a retrospective Spanish multicentric study

    Journal of Pediatric Gastroenterology and Nutrition, Vol. 62, Núm. 2, pp. 284-291

2015

  1. Resources utilization and costs the year before and after starting treatment with adalimumab in Crohn's disease patients

    Inflammatory Bowel Diseases, Vol. 21, Núm. 7, pp. 1631-1640

  2. Vitamin D and chronic lung colonization in pediatric and young adults cystic fibrosis patients

    Nutricion Hospitalaria, Vol. 32, Núm. 4, pp. 1629-1635